CNGA3 and achromatopsia: To evaluate the efficiency of the newly engineered capsids in a relevant preclinical disease model, we performed a proof‐of‐concept gene supplementation study in the Cnga3−/− mouse model of achromatopsia (Biel et al, 1999) using the cone‐favouring AAV2.GL capsid (Table 1).